KOPRANNSEKopran Limited· PharmaceuticalsMediumNeutral
Announced Thu, 30 Apr · 18:15 IST

Kopran Limited has informed the Exchange about Amalgamation/Merger

Nclt Scheme FiledStrategic Transactions View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.6%1-day move
₹164.90
prior close
₹168.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.4+0.3+0.4-0.6-0.3+0.3-2.0-3.8-6.2+14.6+12.2+18.1
Up moveDown movePending
AI summary

Kopran Limited has informed exchanges that the National Company Law Tribunal (NCLT), Mumbai Bench, has ordered meetings of equity shareholders, secured creditors, and unsecured creditors of both Kopran Limited and Kopran Laboratories Limited to consider the proposed merger by absorption of Kopran Laboratories into Kopran Limited. The NCLT order was issued on April 09, 2026, and the six meetings (three for each company) are scheduled for June 03, 2026, to be held via video conferencing. The scheme is being pursued under Sections 230 to 232 of the Companies Act, 2013. Notices are being dispatched electronically to shareholders and creditors, with the full scheme documents made available on the company's website.

Likely market impact

This is a procedural step in an internal group restructuring where a subsidiary (Kopran Laboratories) is being merged into the listed parent (Kopran Limited). Shareholders will get to vote on the scheme on June 3, 2026; outcome of the vote and any swap ratio (once announced) will be the key things to watch. Near-term share price impact is usually limited unless material value is being transferred or a favorable share-swap ratio is offered.